KRAS and familial pancreatic carcinoma: Aberrant activation of different signaling pathways is involved in the pathogenesis of pancreatic cancer.64 Additionally, inhibition of these proliferative signals showed satisfactory efficacy in preclinical studies of pancreatic cancer.64 As mentioned previously, KRAS mutation is a major propellant for the initiation and progression of pancreatic cancer.